A reference post rather than a discussion. Corrections are the point; I would rather this be right than mine. It is about the baseline and follow-up panel, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value. One out-of-range result in isolation generates anxiety and unnecessary tests; the same result next to the trend and the rest of the panel usually generates a shrug.
The condition it depends on
One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.
The practical version
Post reference ranges alongside numbers when you share them. Units differ by country — glucose and lipids especially — and half the confusion in these threads is unit mismatch rather than disagreement.
What I am not sure about
What would genuinely help is knowing what actually belongs on a baseline panel, as opposed to the enormous list that gets pasted around here. Practical detail welcome, however dull — the duller the better.
wei_SG said:The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.
wei_SG has the substance of this right. The condition it depends on is worth stating. Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c becomes informative again, since it reflects about three months of glycaemia. After the first year, and once doses are stable, annual is reasonable unless something specific is being followed.
wei_SG said:The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.
I read this differently from wei_SG, on substance rather than tone. I would drop the "get everything" instinct further than this thread does. Every extra test is another chance at a false positive, and incidental findings have their own cost in scans, biopsies and worry.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsShort answer first, then the reasoning. A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin and B12, and a full blood count. That set catches the things that change, the things that explain symptoms, and the things that alter the prescribing decision. Almost everything else on the long circulating lists is either invariant, uninterpretable without a specific question, or an incidental finding waiting to cause an unnecessary workup.
BethLabQueen said:Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c…
This is my experience too, for whatever a second data point is worth.